On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Geyser Brands Inc. (TSX.V: GYSR) Delivers Established Cannabis Labels to Consumer Health Care Markets

  • Geyser Brands recently received a processing license and implemented manufacturing at a licensed production (LP) facility
  • The company developed NanoFusion, an advanced nanotechnology drug-delivery system
  • GYSR recently acquired Solace Management Group Inc.

Now that cannabis is losing its illegitimacy, derivatives of the plant are permeating consumer markets at a rapidly growing pace, thanks to companies such as Geyser Brands Inc. (TSX.V: GYSR). The global cannabis-powered and science-led consumer health care company offers products in a diverse range of markets, from fast-moving consumer goods and over-the-counter pharmaceuticals to medical cannabis.

In October 2018, Geyser received its Health Canada cultivation license and, in June 2019, less than a year later, a standard processing license. Licenses for R&D and sales are pending. In addition, the company recently closed an acquisition that considerably increased its brand portfolio. Driven by a management team experienced in manufacturing and marketing, Geyser looks set to realize its vision of being a global player in the billion-dollar cannabis and plant-powered health care markets.

Given the company’s extensive brand portfolio, the world is Geyser’s oyster. GYSR has products in a number of global markets, including the trillion-dollar personal and skin-care market; the $575 billion personalized and complementary medicine market; the ballooning (CAGR 34.6 percent) legal-marijuana market, which has been forecasted to reach $146 billion by 2025; the $4.2 trillion wellness market; and the pet care market, which is worth around $132 billion.

Geyser recently closed on its acquisition of established hemp-brands manufacturer Solace Management Group Inc., which added two dozen wellness products and 57 SKUs to GYSR’s product lineup. The acquisition also comes with a 7,500-square-foot, GMP-compliant facility belonging to an existing innovation-hub and manufacturing subsidiary in Coquitlam, British Columbia (http://ibn.fm/StIcV).

Solace also owns a number of brands with leading market positions in Canada, including Apawthecary Pets, WildTails pet products, Apothecary Naturals and Apothecary Ink, all of which currently use hemp oil in their formulations. The brands are distributed by leading retailers across Canada including Bosley’s and Shoppers Drug Mart. In addition, Solace recently received approval for sales of a new pain-relief, roll-on product thanks to a natural product number issued by Health Canada (http://ibn.fm/yXFxK).

And that’s not the only good news for Geyser. In June 2019, Apothecary Botanicals, Geyser’s wholly owned licensed producer (LP), received a standard processing license from Health Canada, a key development that allows the production of a variety of products including tinctures and supplements (http://ibn.fm/Iym76).

In addition, Geyser has developed NanoFusion, an advanced nanotechnology drug-delivery system that transports therapeutic agents rapidly and efficiently directly to the bloodstream for maximum absorbency. In the past, a major challenge in producing cannabinoids for ingestion or absorption through the skin is their insolubility.

Cannabinoids are naturally hydrophobic (afraid of water), which makes it harder for the body to absorb them. The result is inconsistent, unreliable dosing and onset times of up to three hours. Geyser’s NanoFusion breaks down cannabinoid particles and combines them with naturally occurring surfactants that lower the surface tension between cannabinoids and water, resulting in a compound that is water compatible.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.